Shares in artificial heart maker Carmat slumped on Thursday after France’s national drugs agency ordered it to suspend further implants following the death of a patient in October. Carmat shares were down by 18.5 percent at 27.50 euros in morning trading, with around 40 million euros ($42.5 million) wiped off its stock market value. Carmat Chief Executive Stephane Piat said in a statement on Wednesday that the artificial heart was not involved in the patient’s death, and that the company’s last three implantations had functioned normally.
See original here:
Carmat shares slump after French drugs agency suspends its heart implants
